Use of aldosterone antagonists in heart failure

JAMA

Volumn 302, Issue 15, 2009, Pages 1658-1665

  Albert, Nancy M ^a   Yancy, Clyde W ^b   Liang, Li ^c   Zhao, Xin ^c   Hernandez, Adrian F ^c   Peterson, Eric D ^c   Cannon, Christopher P ^d   Fonarow, Gregg C ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; CREATININE; POTASSIUM;

ADULT; AFRICAN AMERICAN; AGED; ANAMNESIS; ARTICLE; CREATININE BLOOD LEVEL; DEFIBRILLATOR; DEPRESSION; ETHNICITY; FEMALE; GROUPS BY AGE; HEART FAILURE; HOSPITAL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMPLANT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RACE; REGISTER; SINUS NODE; SYSTOLIC BLOOD PRESSURE; TREATMENT CONTRAINDICATION; DRUG UTILIZATION; HEALTH CARE QUALITY; MIDDLE AGED; UNITED STATES;

AGED; ALDOSTERONE ANTAGONISTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; REGISTRIES; UNITED STATES;

EID: 70350733579     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1493     Document Type: Article

References (24)

1. Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1-e90.
2. Pitt B, Zannad F, Remme WJ, et al; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717.
3. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J. 2009;30(4):469-477.
4. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551.
5. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation. 2005;112 (1):39-47.
6. Smaha LA; American Heart Association. The American Heart Association Get With The Guidelines program. Am Heart J. 2004;148(5)(suppl):S46-S48.
7. LaBresh KA, Gliklich R, Liljestrand J, Peto R, Ellrodt AG. Using "Get With The Guidelines" to improve cardiovascular secondary prevention. JtCommJ Qual Saf. 2003;29(10):539-550.
8. Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298(13):1525-1532. (Pubitemid 47529386)
9. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049-1060.
10. Fonarow GC, Yancy CW, Albert NM, et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE-HF [published online ahead of print May 28, 2008]. Circ Heart Fail. 2008;1:98-106. doi:10.1161/circheartfailure.108.772228.
11. Nieminen MS, Brutsaert D, Dickstein K, et al; EuroHeart Survey Investigators, Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27(22):2725-2736.
12. Hunt SA, Abraham WT, Chin MH, et al. ACC/ AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) [published correction appears in J Am Coll Cardiol. 2006;47(7):1502-1503]. J Am Coll Cardiol. 2005;46(6):1116-1143.
13. Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. ACC/ AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society [published correction appears in Circulation. 2006;113:e684-e685]. Circulation. 2005;112(12): e154-e235.
14. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41(2):211-214. (Pubitemid 36092186)
15. Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone- induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J. 2004;148(6):971-978. (Pubitemid 39646969)
16. Svensson M, Gustafsson F, Galatius S, Hildebrant PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297-303. (Pubitemid 39092680)
17. Williams EM, Katholi RE, Karambelas MR. Use and side-effect profile of spironolactone in a private cardiologist's practice. Clin Cardiol. 2006;29(4):149-153.
18. Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y. Serum concentration of potassium in chronic heart failure patients administered sprionolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. J Clin Pharm Ther. 2005;30(6):603-610.
19. Hu Y, Carpenter JP, Cheung AT. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency. Anesth Analg. 2002;95(1):39-41. (Pubitemid 34705549)
20. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46(5):845-849. (Pubitemid 41224809)
21. Raebel MA, McClure DL, Chan KA, et al. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? Ann Pharmacother. 2007;41(2):193-200. (Pubitemid 46340049)
22. Krantz MJ, Tanner J, Horwich TB, et al; Get With the Guidelines Steering Committee and Hospitals. Influence of hospital length of stay for heart failure on quality of care. Am J Cardiol. 2008;102(12):1693-1697.
23. Erhardt L, Komajda M, Hobbs FD, Soler-Soler J. Cardiologists' awareness and perceptions of guidelines for chronic heart failure: the ADDress your Heart survey. Eur J Heart Fail. 2008;10(10):1020-1025.
24. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585-592.